SHANGHAI – Ark Biosciences Inc. successfully completed a phase I trial for AK0529, an oral drug designed to treat respiratory syncytial virus (RSV), a common virus that can be deadly in premature infants, children and the elderly by infecting the lungs and respiratory tract.